major histocompatibility complex class I tagged posts

A long noncoding RNA whose function was previously unknown turns out to play an important role in promoting the body’s immune response against cancer and holds promise for enhancing the efficacy of anti-cancer immunotherapy.

That’s according to new findings reported in Nature Cell Biology by researchers at the University of Michigan Rogel Cancer Center.

The group dubbed the RNA they identified LIMIT—for long noncoding RNA inducing major histocompatibility complex class I and immunogenicity of tumor.

“LIMIT is easy to remember, but really it does the opposite. It stimulates immune functions against cancer,” says senior study author Weiping Zou, M.D., Ph.D., the Charles B...